Ionis will receive $280 million upfront and could get up to $660 million in future milestone payments. Ono will take charge of late-stage development as well as regulatory and commercialization activities.
Ionis Sends Polycythemia Vera Drug to Ono in Licensing Deal Worth Nearly $1B Biobucks